Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Apr
21
Today In Oncology
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Elisrasib Demonstrates High DCR in KRAS G12C NSCLC
Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival
Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy
Advanced Platinum-Resistant Ovarian Cancer: Investigational ADC Shows Activity
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo